JP2015505541A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505541A5
JP2015505541A5 JP2014553622A JP2014553622A JP2015505541A5 JP 2015505541 A5 JP2015505541 A5 JP 2015505541A5 JP 2014553622 A JP2014553622 A JP 2014553622A JP 2014553622 A JP2014553622 A JP 2014553622A JP 2015505541 A5 JP2015505541 A5 JP 2015505541A5
Authority
JP
Japan
Prior art keywords
nasal
carrier material
powder
inhaled
nose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553622A
Other languages
English (en)
Japanese (ja)
Other versions
JP6063482B2 (ja
JP2015505541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/005358 external-priority patent/WO2013110309A1/en
Publication of JP2015505541A publication Critical patent/JP2015505541A/ja
Publication of JP2015505541A5 publication Critical patent/JP2015505541A5/ja
Application granted granted Critical
Publication of JP6063482B2 publication Critical patent/JP6063482B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553622A 2012-01-28 2012-12-21 トリアゾロ［４，５−ｄ］ピリミジン誘導体 Expired - Fee Related JP6063482B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12000558 2012-01-28
EP12000558.2 2012-01-28
PCT/EP2012/005358 WO2013110309A1 (en) 2012-01-28 2012-12-21 Triazolo[4,5-d]pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2015505541A JP2015505541A (ja) 2015-02-23
JP2015505541A5 true JP2015505541A5 (enExample) 2016-12-15
JP6063482B2 JP6063482B2 (ja) 2017-01-18

Family

ID=47561514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553622A Expired - Fee Related JP6063482B2 (ja) 2012-01-28 2012-12-21 トリアゾロ［４，５−ｄ］ピリミジン誘導体

Country Status (15)

Country Link
US (1) US9409914B2 (enExample)
EP (1) EP2807161B1 (enExample)
JP (1) JP6063482B2 (enExample)
KR (1) KR20140117636A (enExample)
CN (1) CN104066734B (enExample)
AR (1) AR089810A1 (enExample)
AU (1) AU2012367141B2 (enExample)
BR (1) BR112014016884A2 (enExample)
CA (1) CA2862694C (enExample)
ES (1) ES2655264T3 (enExample)
IL (1) IL233808B (enExample)
MX (1) MX2014008864A (enExample)
SG (1) SG11201404234YA (enExample)
WO (1) WO2013110309A1 (enExample)
ZA (1) ZA201406323B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164136B (zh) * 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
JP6966423B2 (ja) * 2015-04-24 2021-11-17 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
HUE069702T2 (hu) * 2016-08-10 2025-04-28 Takeda Pharmaceuticals Co Heterociklusos vegyület
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
KR102328423B1 (ko) * 2018-09-11 2021-11-18 재단법인 대구경북첨단의료산업진흥재단 신규 트리아졸로-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP3860578A1 (en) * 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
WO2021222147A1 (en) * 2020-04-27 2021-11-04 Hibercell, Inc. Heterocyclic gcn2 modulators
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
KR20250122240A (ko) 2024-02-06 2025-08-13 한미약품 주식회사 신규한 함질소 헤테로고리 유도체 및 이의 용도
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
CN120504636B (zh) * 2025-07-22 2025-10-31 江西中医药大学 一种磺胺噻唑-甲氧苄啶药物晶盐及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
CA2531333A1 (en) 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
DE102004051827A1 (de) 2004-10-25 2006-05-04 Hörmann KG Antriebstechnik Armbandsender
ES2508766T3 (es) * 2004-10-29 2014-10-16 Janssen R&D Ireland Derivados de pirimidina bicíclicos que inhiben el VIH
RU2007130893A (ru) 2005-01-14 2009-02-20 Янссен Фармацевтика Н.В. (Be) Производные триазолопиримидина
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
CN102666545B (zh) 2009-10-20 2016-04-06 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物

Similar Documents

Publication Publication Date Title
JP2014526447A5 (enExample)
JP2013544781A5 (enExample)
JP2014509313A5 (enExample)
JP2015505541A5 (enExample)
JP2013534227A5 (enExample)
JP2013541565A5 (enExample)
BR112013022249B8 (pt) Dispositivo de distribuição de droga nasal
WO2014074797A8 (en) Ultra low density pulmonary powders
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
IN2014DN09377A (enExample)
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
SA515361262B1 (ar) تركيبات من مركبات نشطة صيدليا تحتوي على ثاني إثيلين جليكول أول إثيل إثير أو مشتقات ألكيل أخرى
JP2014528470A5 (enExample)
CL2013000958A1 (es) Dispositivo atomizador nasal para la administracion de una formulacion farmaceutica a traves de la cavidad nasal en dosis controladas, comprende: un cartucho de aerosol presurizado que a su vez incluye un frasco con una formulacion farmaceutica, el accionador comprende una salida de administracion para el penacho de aerosol, donde el orificio de descarga se encuentra dispuesto de manera de dirigir el penacho de aerosol a traves de la salida de administracion; uso.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
EA201690541A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
WO2013038267A8 (en) Tamper resistant pharmaceutical formulations
WO2013038268A8 (en) Tamper resistant immediate release formulations
JP2014530231A5 (enExample)
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
AR099364A1 (es) Inhalador de medicamentos
MD20160061A2 (ro) Sistem de livrare a medicamentului compus din particule multiple
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.